| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update JS Smolen, R Landewé, J Bijlsma, G Burmester, K Chatzidionysiou, ... Annals of the rheumatic diseases 76 (6), 960-977, 2017 | 5726 | 2017 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update JS Smolen, RBM Landewé, JWJ Bijlsma, GR Burmester, M Dougados, ... Annals of the rheumatic diseases 79 (6), 685-699, 2020 | 2599 | 2020 |
| Psoriatic arthritis: epidemiology, clinical features, course, and outcome DD Gladman, C Antoni, P Mease, DO Clegg, P Nash Annals of the rheumatic diseases 64 (suppl 2), ii14-ii17, 2005 | 1991 | 2005 |
| Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force JS Smolen, FC Breedveld, GR Burmester, V Bykerk, M Dougados, ... Annals of the rheumatic diseases 75 (1), 3-15, 2016 | 1644 | 2016 |
| Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis LC Coates, A Kavanaugh, PJ Mease, ER Soriano, ... Arthritis & rheumatology 68 (5), 1060-1071, 2016 | 1076 | 2016 |
| Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis PJ Mease, IB McInnes, B Kirkham, A Kavanaugh, P Rahman, ... New England Journal of Medicine 373 (14), 1329-1339, 2015 | 862 | 2015 |
| Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed LBA Van de Putte, C Atkins, M Malaise, J Sany, AS Russell, P Van Riel, ... Annals of the rheumatic diseases 63 (5), 508-516, 2004 | 782 | 2004 |
| Treatment recommendations for psoriatic arthritis CT Ritchlin, A Kavanaugh, DD Gladman, PJ Mease, P Helliwell, ... Annals of the rheumatic diseases 68 (9), 1387-1394, 2009 | 736 | 2009 |
| Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four–month phase III randomized radiographic study D Van Der Heijde, Y Tanaka, R Fleischmann, E Keystone, J Kremer, ... Arthritis & Rheumatism 65 (3), 559-570, 2013 | 632 | 2013 |
| Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double‐blind, randomized, placebo‐controlled clinical trial JP Kaltwasser, P Nash, D Gladman, CF Rosen, F Behrens, P Jones, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2004 | 595 | 2004 |
| Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis … P Emery, RM Fleischmann, LW Moreland, EC Hsia, I Strusberg, P Durez, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2009 | 547 | 2009 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update JS Smolen, RBM Landewé, SA Bergstra, A Kerschbaumer, A Sepriano, ... Annals of the rheumatic diseases 82 (1), 3-18, 2023 | 504 | 2023 |
| Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised … JS Smolen, P Nash, P Durez, S Hall, E Ilivanova, F Irazoque-Palazuelos, ... The Lancet 381 (9870), 918-929, 2013 | 444 | 2013 |
| Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised … P Nash, B Kirkham, M Okada, P Rahman, B Combe, GR Burmester, ... The Lancet 389 (10086), 2317-2327, 2017 | 442 | 2017 |
| The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: results of a twelve‐month, multicenter, exploratory … JT Merrill, R Burgos‐Vargas, R Westhovens, A Chalmers, D D'cruz, ... Arthritis & Rheumatism 62 (10), 3077-3087, 2010 | 433 | 2010 |
| Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials SB Cohen, Y Tanaka, X Mariette, JR Curtis, EB Lee, P Nash, KL Winthrop, ... Annals of the rheumatic diseases 76 (7), 1253-1262, 2017 | 390 | 2017 |
| Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double‐blind, placebo‐controlled, dose‐ranging study J Kay, EL Matteson, B Dasgupta, P Nash, P Durez, S Hall, EC Hsia, J Han, ... Arthritis & Rheumatism 58 (4), 964-975, 2008 | 385 | 2008 |
| Consensus on a core set of domains for psoriatic arthritis. DD Gladman, PJ Mease, V Strand, P Healy, PS Helliwell, O Fitzgerald, ... The Journal of rheumatology 34 (5), 1167-1170, 2007 | 344 | 2007 |
| The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project) PS Helliwell, O FitzGerald, J Fransen, DD Gladman, GG Kreuger, ... Annals of the rheumatic diseases 72 (6), 986-991, 2013 | 312 | 2013 |
| Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update MA Stoffer, MM Schoels, JS Smolen, D Aletaha, FC Breedveld, ... Annals of the rheumatic diseases 75 (1), 16-22, 2016 | 306 | 2016 |
